Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Vir Biotechnology, Inc.
NASDAQ:VIRHealthcare · Biotechnology
-3.83%$11.30
AH$11.66+3.19%vs close
Mkt Cap$1.91B
Float132.16M
O/S169.22M
Vol
$ Vol
RVOL
Inst Own86.7%
SI12.3%
Earnings
Dilution
Financials Summary
Revenue$68.56M
Net Income-$437.99M
Total Assets$1B
Free Cash Flow-$396.61M
Debt & Equity
Debt 20%
Equity 80%
Total Debt$186.91M
Total Equity$765.28M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in VIR's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$1B
Liabilities$237.55M
Accounts Receivable$3.6M
Accounts Payable$9.8M
Inventory$0
PP&E (Net)$117.72M
Goodwill$16.94M
Intangible Assets$7.85M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Revenue | $68.56M | $74.2M | $86.18M | $1.62B | $1.1B | $76.37M | $8.09M | $10.67M | $2.71M |
| YoY Growth | -7.6% | -13.9% | -94.7% | 47.5% | 1334.4% | 843.9% | -24.2% | 293.9% | - |
| Cost of Revenue | $11.71M | $15.4M | $22.22M | $161.81M | $71.68M | $0 | $0 | $0 | $0 |
| Gross Profit | $56.85M | $58.8M | $63.96M | $1.45B | $1.02B | $0 | $0 | $0 | $0 |
| Gross Margin | 82.9% | 79.2% | 74.2% | 90.0% | 93.5% | - | - | - | - |
| Research and Development | $432.8M | $463.19M | $550.92M | $467.87M | $442.19M | $296.14M | $139.47M | $97.47M | $62.08M |
| Selling, General, and Administrative | $92.07M | $119.03M | $174.05M | $153.05M | $160.79M | $67.57M | $37.6M | $29.13M | $20.99M |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $524.87M | $582.22M | $724.97M | $620.92M | $602.99M | $363.7M | $177.07M | $126.6M | $83.07M |
| Operating Income (EBIT) | -$468.02M | -$523.42M | -$661M | $833.07M | $420.75M | -$296.15M | -$173.5M | -$118.69M | -$80.8M |
| Operating Margin | -682.7% | -705.4% | -767.0% | 51.6% | 38.4% | -387.8% | -2144.3% | -1112.6% | -2983.6% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $40.24M | $71.81M | $86.99M | $28.09M | $439K | $2.84M | $8.51M | $2.54M | $638K |
| Other Income (Expense) | $30.25M | $316K | $32.81M | -$78.79M | $129.05M | -$2.46M | -$1.03M | $2.33M | $21K |
| Income Before Tax (EBT) | -$437.77M | -$523.11M | -$628.19M | $754.28M | $549.8M | -$298.61M | -$174.53M | -$116.36M | -$80.78M |
| Income Tax Expense | $217K | -$1.15M | -$13.08M | $238.44M | $21.22M | $54K | $154K | -$480K | -$10.92M |
| Net Income | -$437.99M | -$521.96M | -$615.06M | $515.84M | $528.58M | -$298.67M | -$174.68M | -$115.88M | -$69.85M |
| Net Income Margin | -638.9% | -703.4% | -713.7% | 31.9% | 48.3% | -391.1% | -2159.0% | -1086.3% | -2579.5% |
| Supplementary Data | |||||||||
| EPS | -3.16 | -3.83 | -4.59 | 3.89 | 4.07 | -2.51 | -1.62 | -1.20 | -10.02 |
| Diluted EPS | -3.16 | -3.83 | -4.59 | 3.83 | 3.96 | -2.51 | -1.62 | -1.20 | -10.02 |
| Weighted Average OS | 138.52M | 136.25M | 134.13M | 132.61M | 129.88M | 119.16M | 107.65M | 96.91M | 6.97M |
| EBITDA | -$456.34M | -$508.86M | -$641.55M | $848.56M | $432.73M | -$287.33M | -$168.98M | -$115.94M | -$80.36M |
| EBITDA Margin | -665.6% | -685.8% | -744.4% | 52.5% | 39.5% | -376.3% | -2088.5% | -1086.8% | -2967.7% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Assets | |||||||||
| Current Assets | |||||||||
| Cash and Cash Equivalents | $234.11M | $222.95M | $241.58M | $848.63M | $347.81M | $436.57M | $109.33M | $47.6M | $187.92M |
| Short-Term Investments | $228.75M | $682.4M | $1.28B | $1.55B | $360.33M | $300.29M | $274.1M | $50.84M | $0 |
| Cash and Short-Term Investments | $462.86M | $905.35M | $1.52B | $2.4B | $708.14M | $736.86M | $383.44M | $98.44M | $187.92M |
| Accounts Receivable | $3.6M | $0 | $0 | $0 | $773.08M | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $47.62M | $137.11M | $65.82M | $59.2M | $8.59M | $7.99M | $6.18M | $10.76M | $0 |
| Total Current Assets | $514.08M | $1.04B | $1.59B | $2.52B | $1.56B | $772.37M | $403M | $117.78M | $192.35M |
| Long-Term Assets | |||||||||
| Property, Plant & Equipment Net | $117.72M | $122.86M | $167.2M | $188.17M | $130.05M | $79.89M | $16.31M | $12.29M | $5.14M |
| Goodwill | $16.94M | $16.94M | $16.94M | $16.94M | $16.94M | $16.94M | $16.94M | $16.94M | $16.94M |
| Intangible Assets | $7.85M | $8.1M | $22.57M | $32.76M | $33.29M | $33.82M | $35.66M | $36.92M | $35.88M |
| Long-Term Investments | $314.57M | $190.01M | $105.28M | $23.93M | $201.39M | $0 | $24.29M | $7.67M | $1M |
| Deferred Tax Assets | $0 | $0 | $0 | $249.72M | $0 | $0 | $0 | -$7.67M | -$1M |
| Other Long-Term Assets | $31.66M | $18.42M | $18.86M | -$228.5M | $9.78M | $15.75M | $15.85M | $7.67M | $1.26M |
| Total Long-Term Assets | $488.74M | $356.33M | $330.83M | $283.01M | $391.45M | $146.4M | $109.04M | $73.81M | $59.22M |
| Other Assets | $0 | $22K | $0 | $0 | $0 | $0 | $33K | $0 | $0 |
| Total Assets | $1B | $1.4B | $1.92B | $2.8B | $1.95B | $918.76M | $512.07M | $191.6M | $251.57M |
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts Payable | $9.8M | $5.08M | $6.33M | $6.42M | $6.52M | $5.08M | $5.88M | $6.47M | $4.9M |
| Short-Term Debt | $8.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $149K | $15.23M | $6.22M | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $12.65M | $64.85M | $15.52M | $98.21M | $6.45M | $6.18M | $8.76M | $0 |
| Other Current Liabilities | $74.21M | $16.06M | $9.35M | $7.65M | $0 | $10.6M | $22.08M | $22.02M | $0 |
| Total Current Liabilities | $92.81M | $119.66M | $175.41M | $511.03M | $341.24M | $99.06M | $59.21M | $39.91M | $12.44M |
| Long-Term Liabilities | |||||||||
| Long-Term Debt | $89.05M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $1.53M | $53.21M | $3.81M | $3.81M | $12.67M | $6.56M | $888K |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $3.25M | $18.44M | $3.25M | $3.31M | $3.31M | $3.31M |
| Other Long-Term Liabilities | -$33.38M | $38.63M | $40.22M | $32.8M | $25.36M | $29.22M | $12.95M | $10.84M | $10.4M |
| Total Long-Term Liabilities | $144.73M | $128.77M | $153.42M | $213.1M | $181.18M | $102.84M | $28.92M | $330.87M | $308.04M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $237.55M | $248.43M | $328.82M | $724.13M | $522.42M | $201.91M | $88.13M | $370.77M | $320.48M |
| Stockholders' Equity | |||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $309.14M | $292.52M |
| Common Stock | $14K | $14K | $13K | $13K | $13K | $13K | $11K | $1K | $1K |
| Retained Earnings | -$1.2B | -$759.78M | -$237.82M | $377.24M | -$138.6M | -$667.18M | -$368.52M | -$193.84M | -$77.95M |
| Comprehensive Income & Other | -$2.06M | -$1.72M | -$815K | -$9.12M | -$1.1M | -$1.28M | -$601K | -$14K | -$292.52M |
| Other Stockholders' Equity | $1.96B | $1.91B | $1.83B | $1.7B | $1.57B | $1.38B | $792.45M | $14.66M | $9.04M |
| Total Equity | $765.28M | $1.15B | $1.59B | $2.08B | $1.43B | $716.85M | $423.94M | -$179.18M | -$68.92M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $1B | $1.4B | $1.92B | $2.8B | $1.95B | $918.76M | $512.07M | $191.6M | $251.57M |
| Supplementary Data | |||||||||
| Total Debt | $186.91M | $97.89M | $124.54M | $127.97M | $137.49M | $70.18M | $237K | $10.14M | $0 |
| Net Debt | -$47.2M | -$125.06M | -$117.04M | -$720.66M | -$210.33M | -$366.39M | -$109.1M | -$37.46M | -$187.92M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Operating Activities | |||||||||
| Net Income | -$437.99M | -$521.96M | -$615.06M | $515.84M | $528.58M | -$298.67M | -$174.68M | -$115.88M | -$69.85M |
| Depreciation & Amortization | $11.68M | $14.56M | $19.45M | $6.78M | $5.81M | $5.44M | $4.52M | $2.76M | $432K |
| Deferred Income Tax | $0 | -$2.95M | -$1.06M | -$15.19M | $15.19M | -$52K | $0 | -$480K | -$10.92M |
| Stock-Based Compensation | $49.07M | $78.46M | $0 | $102.08M | $83.78M | $27.6M | $8.72M | $5.05M | $4.78M |
| Changes in Working Capital: | |||||||||
| Accounts Receivable | $0 | -$6.51M | -$565K | $770.04M | -$773.08M | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $52.81M | $0 | $0 | $0 | $0 |
| Accounts Payable | $5M | -$988K | $732K | $797K | -$171K | -$790K | $964K | $1.47M | $2.01M |
| Other Working Capital | -$27.44M | -$76.51M | -$304.76M | -$105.47M | $92.04M | $30.31M | $7.24M | $11.02M | $2.85M |
| Total Working Capital Change | -$22.45M | -$84.01M | -$304.59M | $665.37M | -$628.39M | $29.52M | $8.2M | $12.49M | $4.86M |
| Other Non-Cash Items | $7.9M | $69.55M | $122.48M | $388.37M | -$52.56M | $45.21M | $23.61M | $1.97M | $4.32M |
| Net Cash from Operating | -$391.78M | -$446.35M | -$778.78M | $1.66B | -$47.59M | -$190.94M | -$129.63M | -$94.1M | -$66.38M |
| Investing Activities | |||||||||
| Capital Expenditures | -$4.83M | -$7.3M | -$21.57M | -$68.01M | -$21.82M | -$6.55M | -$8.94M | -$8.19M | -$2.74M |
| Acquisitions | $253K | $3.37M | $100K | $0 | $140.81M | $0 | $0 | $25K | -$27.25M |
| Purchases of Investments | -$886.33M | -$1.24B | -$2.02B | -$1.48B | -$420.24M | -$403.84M | -$643.9M | -$123.11M | $0 |
| Sales of Investments | $1.2B | $1.74B | $2.2B | $351.51M | $301.24M | $400.35M | $396.68M | $72.57M | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | -$140.81M | $180K | $0 | -$1.74M | $0 |
| Net Cash from Investing | $310.37M | $499.37M | $164.73M | -$1.19B | -$140.81M | -$9.86M | -$256.16M | -$60.44M | -$29.99M |
| Financing Activities | |||||||||
| Debt Repaid | $361K | $165K | $287K | $260K | $259K | $250K | -$4.37M | - | - |
| Common Stock Issuance | $4.15M | $4.55M | $7.77M | $28.46M | $85.21M | $529.91M | $126.41M | $24.98M | $271.18M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | -$3K | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $0 | -$100K | $6.56M | $15.38M | -$189K | $1.13M | $584K | $0 |
| Net Cash from Financing | $3.79M | $4.39M | $7.38M | $34.76M | $100.33M | $529.47M | $449.24M | $24.98M | $271.18M |
| Forex Effect | $0 | $0 | $208K | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$77.63M | $57.4M | -$606.47M | $504.55M | -$88.07M | $328.67M | $63.45M | -$129.56M | $174.81M |
| Supplementary Data | |||||||||
| Operating Cash Flow | -$391.78M | -$446.35M | -$778.78M | $1.66B | -$47.59M | -$190.94M | -$129.63M | -$94.1M | -$66.38M |
| Capital Expenditure | -$4.83M | -$7.3M | -$21.57M | -$68.01M | -$21.82M | -$6.55M | -$8.94M | -$8.19M | -$2.74M |
| Free Cash Flow | -$396.61M | -$453.65M | -$800.36M | $1.6B | -$69.41M | -$197.49M | -$138.57M | -$102.29M | -$69.12M |
| Cash at Beginning | $318.69M | $261.29M | $861.31M | $363.42M | $451.49M | $122.82M | $59.36M | $188.92M | $14.11M |
| Cash at End | $241.07M | $318.69M | $254.84M | $867.97M | $363.42M | $451.49M | $122.82M | $59.36M | $188.92M |